S&P 500   3,000.76 (+0.16%)
DOW   26,880.13 (+0.34%)
QQQ   191.92 (+0.04%)
AAPL   242.64 (+1.12%)
FB   185.14 (+1.53%)
MSFT   136.19 (-0.14%)
GOOGL   1,255.20 (+1.13%)
AMZN   1,765.37 (-0.02%)
CGC   21.05 (-0.47%)
NVDA   194.10 (-0.77%)
MU   44.14 (-1.16%)
BABA   168.74 (-0.68%)
GE   9.02 (-0.44%)
TSLA   254.23 (-0.53%)
AMD   31.37 (-0.44%)
T   38.11 (-0.18%)
F   9.03 (-0.44%)
ACB   3.58 (+0.00%)
NFLX   271.73 (+1.89%)
BAC   31.34 (+0.45%)
GILD   65.92 (+0.09%)
DIS   131.90 (-0.38%)
S&P 500   3,000.76 (+0.16%)
DOW   26,880.13 (+0.34%)
QQQ   191.92 (+0.04%)
AAPL   242.64 (+1.12%)
FB   185.14 (+1.53%)
MSFT   136.19 (-0.14%)
GOOGL   1,255.20 (+1.13%)
AMZN   1,765.37 (-0.02%)
CGC   21.05 (-0.47%)
NVDA   194.10 (-0.77%)
MU   44.14 (-1.16%)
BABA   168.74 (-0.68%)
GE   9.02 (-0.44%)
TSLA   254.23 (-0.53%)
AMD   31.37 (-0.44%)
T   38.11 (-0.18%)
F   9.03 (-0.44%)
ACB   3.58 (+0.00%)
NFLX   271.73 (+1.89%)
BAC   31.34 (+0.45%)
GILD   65.92 (+0.09%)
DIS   131.90 (-0.38%)
Log in

Orgenesis Stock Price, News & Analysis (NYSE:ORGS)

$3.68
0.00 (0.00 %)
(As of 10/23/2019 11:14 AM ET)
Today's Range
$3.65
Now: $3.68
$3.65
50-Day Range
$3.59
MA: $4.11
$4.56
52-Week Range
$3.50
Now: $3.68
$6.69
Volume30 shs
Average Volume29,006 shs
Market Capitalization$59.40 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Orgenesis Inc., a service and research company, focus on the development and manufacture of cell therapy for advanced medicinal products in the field of regenerative medicine industry. It operates through two segments, Contract Development and Manufacturing Organizations (CDMO) and Cellular Therapy (CT) Business. The CDMO segment specializes in cell therapy development for advanced medicinal products. This segment provides process and assay development services; and current Good Manufacturing Practices contract manufacturing services. The CT Business segment develops cell trans-differentiation technology induce shift in the developmental fate of cells from the liver and differentiating them into pancreatic beta cell-like insulin producing cells for patients with Type 1 diabetes. The company has a collaboration agreement with CureCell Co., Ltd. to carry out pre-clinical and clinical activities related to the commercialization of autologous insulin producing cell therapy product in Korea; and with BGN Technologies and the National Institute for Biotechnology to develop and commercialize a scaffold technology for cell transplantation, as well as a collaboration and license agreement with Mircod Limited for the research, development, and commercialization of various technologies related to biological sensing for Orgenesis's clinical development and manufacturing projects. It also has a collaboration agreements with Ben-Gurion University and MangoGen Pharma Inc. The company was formerly known as Business Outsourcing Services, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was founded in 2008 and is based in Germantown, Maryland.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone480-659-6404

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$59.40 million
Next Earnings DateN/A
OptionableNot Optionable

Receive ORGS News and Ratings via Email

Sign-up to receive the latest news and ratings for ORGS and its competitors with MarketBeat's FREE daily newsletter.


Orgenesis (NYSE:ORGS) Frequently Asked Questions

What is Orgenesis' stock symbol?

Orgenesis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ORGS."

How were Orgenesis' earnings last quarter?

Orgenesis Inc. (NYSE:ORGS) announced its quarterly earnings results on Monday, August, 12th. The company reported ($0.36) earnings per share for the quarter, missing analysts' consensus estimates of ($0.10) by $0.26. The company had revenue of $7.76 million for the quarter, compared to analyst estimates of $6.38 million. View Orgenesis' Earnings History.

What is the consensus analysts' recommendation for Orgenesis?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Orgenesis in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Orgenesis.

Has Orgenesis been receiving favorable news coverage?

Media headlines about ORGS stock have been trending somewhat positive recently, InfoTrie reports. The research firm identifies positive and negative news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Orgenesis earned a media sentiment score of 0.6 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the near term. View News Stories for Orgenesis.

Who are some of Orgenesis' key competitors?

What other stocks do shareholders of Orgenesis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Orgenesis investors own include China Pharma (CPHI), Janus Henderson Group (JHG), Blackstone Group (BX) and Ares Management (ARES).

Who are Orgenesis' key executives?

Orgenesis' management team includes the folowing people:
  • Ms. Vered Caplan, Chairman, CEO & Pres (Age 49)
  • Prof. Sarah Ferber, Founder & Chief Scientific Officer (Age 64)
  • Mr. Neil T. Reithinger, CFO, Sec. & Treasurer (Age 48)
  • Dr. Denis Bedoret, Gen. Mang. of MaSTHERCELL (Age 37)

How do I buy shares of Orgenesis?

Shares of ORGS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Orgenesis' stock price today?

One share of ORGS stock can currently be purchased for approximately $3.68.

How big of a company is Orgenesis?

Orgenesis has a market capitalization of $59.40 million. View Additional Information About Orgenesis.

What is Orgenesis' official website?

The official website for Orgenesis is http://www.orgenesis.com/.

How can I contact Orgenesis?

The company can be reached via phone at 480-659-6404.


MarketBeat Community Rating for Orgenesis (NYSE ORGS)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  12 (Vote Outperform)
Underperform Votes:  18 (Vote Underperform)
Total Votes:  30
MarketBeat's community ratings are surveys of what our community members think about Orgenesis and other stocks. Vote "Outperform" if you believe ORGS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ORGS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/23/2019 by MarketBeat.com Staff

Featured Article: Float

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel